The funding round was led by Mars Growth Capital with participation from existing backers.
"Reaching profitability while maintaining significant growth demonstrates the strength of our business model and our long-term vision. This success is a testament to the dedication and hard work of our entire team."
The investment round was led by CRH Ventures with participation from existing backers such as SKion Water.
"I am thrilled to announce CRH Ventures’ investment in FIDO which builds on our existing partnership with CRH through its Oldcastle Infrastructure business in the United States. This investment not only secures our company’s future, but it will also allow us to grow at scale in markets we could not easily have reached and to really fulfil our mission of creating a world without water scarcity."
The oversubscribed round was led by SFC Capital with participation from angel investors and early clients.
"The team at Nesti are building one of the most exciting B2B platforms we have seen recently. Nesti is well designed, extremely easy to use and is already proving its effectiveness amongst sales teams. There is an abundance of potential to not only own the generative AI video prospecting space but also expand into horizontal markets. We are excited to be working with the team as they expand and grow."
The round was co-led by World Fund and Maniv to expand the company production and research capabilities.
"Anaphite’s unique technology and smart, tenacious, market-savvy team are set to disrupt the global EV market. Their technology is genuinely market-leading, and will help the world transition to an eco-mobility future. The team has already made breakthroughs in lithium-ion battery production, and their technology will be applicable to a wide range of new battery technologies, including sodium-ion and solid state. Anaphite has the potential for exponential growth, and we at World Fund are proud to be supporting them as they grow."
The Series A round was led by Ahren, OMX Ventures, and Paladin Capital Group to develop biomanufacturing platforms.
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery,"